<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01742507</url>
  </required_header>
  <id_info>
    <org_study_id>UW 12-093</org_study_id>
    <nct_id>NCT01742507</nct_id>
  </id_info>
  <brief_title>A Study Comparing Two Stent on the Degree of Early Stent Healing and Late Lumen Loss.The OCT-ORION Study</brief_title>
  <acronym>OCT-ORION</acronym>
  <official_title>A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss.The OCT-ORION Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stent coverage and neo-intimal growth can be evaluated in-detail by intracoronary optical
      coherence tomography (OCT), which is a catheter-based imaging technique. It is performed as
      part of the PCI procedure. OCT is the optical analogue of intravascular ultrasound (IVUS),
      except that it can provide much higher resolution of coronary cross sectional images than
      IVUS. The LightLab C7XR OCT system (Frequency Domain OCT) used in this Hospital has obtained
      full CE Mark, approved by the US FDA, and approved for clinical use in Hong Kong. It has been
      shown to be safe in clinical settings and has been used in over 300 patients without
      complication at Queen Mary Hospital.

      In this study, stent coverage and neo-intimal growth between zotarolimus-eluting stents (ZES)
      and biolimus-eluting stents (BES) will be compared by using OCT at 9 month and specific
      post-intervention re-study intervals.

      The investigators objective is to investigate the clinical impact and OCT difference on early
      stent healing and late lumen loss between the two new-generation limus-eluting-stents -
      Resolute Integrity and Biomatrix, which differ in stent design, eluting drug and coating
      polymer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomised, assessor-blinded, single centre study. Patients with
      symptomatic coronary artery diseases in 2 or 3 coronary vessels requiring PCI are eligible
      for the study. PCI will be performed in the usual manner to all the study lesions in the same
      procedure. In a randomized fashion, each patient will have one artery with critical
      disease(s) treated by the Resolute Integrity Stent(s) and the other artery treated by the
      Biomatrix Stent(s).

      Baseline OCT data will be obtained right after stenting. The remaining coronary artery, if
      diseased and required PCI treatment, will be treated during the angiographic and OCT
      follow-up as a staged procedure. Patients will be randomly assigned into 5 groups with equal
      number, receiving a follow-up coronary angiogram with OCT from 2, 3, 4, 5 and 6 months
      interval post-intervention. Each patient will serve as his/her own control comparing the 2
      types of stents. At 9-month post-intervention, all patients will receive a second follow-up
      coronary angiogram with OCT. All OCT data analyses will be performed in a blinded fashion by
      a core laboratory. Phone follow up will be carried out for cardiac events at 1 year and 2
      year of post intervention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• OCT derived percentage stent strut coverage at 9 month</measure>
    <time_frame>9 month</time_frame>
    <description>OCT derived percentage stent strut coverage at 9 month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angiographic binary stenosis</measure>
    <time_frame>9 month</time_frame>
    <description>• Angiographic binary stenosis at 9 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• OCT derived neo-intimal area at 9 month</measure>
    <time_frame>at 9 month</time_frame>
    <description>• OCT derived neo-intimal area at 9 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Minimal lumen diameter by Quantitative Coronary Analysis (QCA) at 9 month</measure>
    <time_frame>9 month</time_frame>
    <description>• Minimal lumen diameter by Quantitative Coronary Analysis (QCA) at 9 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• All major adverse cardiac events (all cardiac deaths, myocardial infarction, target vessel failure and target lesion revascularization, and stent thrombosis) at the pre-defined 2 to 9 months angiographic and OCT follow-up.</measure>
    <time_frame>2 to 9 months</time_frame>
    <description>• All major adverse cardiac events (all cardiac deaths, myocardial infarction, target vessel failure and target lesion revascularization, and stent thrombosis) at the pre-defined 2 to 9 months angiographic and OCT follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Target vessel stent thrombosis per Academic Research Consortium (ARC) definition</measure>
    <time_frame>from enrollment till 2 years follow up</time_frame>
    <description>• Target vessel stent thrombosis per Academic Research Consortium (ARC) definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of stent strut malapposition</measure>
    <time_frame>9 month</time_frame>
    <description>Percentage of stent strut malapposition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean neo-intimal thickness (NIT) at 9 month</measure>
    <time_frame>9 month</time_frame>
    <description>Mean neo-intimal thickness (NIT) at 9 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent volume</measure>
    <time_frame>at 9 month</time_frame>
    <description>Stent volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lumen volume</measure>
    <time_frame>at 9 month</time_frame>
    <description>Lumen volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neointimal Hyperplasia (NIH) volume</measure>
    <time_frame>at 9 month</time_frame>
    <description>Neointimal Hyperplasia (NIH) volume</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Medtronic Resolute Integrity Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medtronic Resolute Integrity Stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biomatrix stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biomatrix stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Resolute Integrity Stent</intervention_name>
    <description>Resolute Integrity Stent</description>
    <arm_group_label>Medtronic Resolute Integrity Stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biomatrix stent</intervention_name>
    <description>Biomatrix stent</description>
    <arm_group_label>Biomatrix stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient aged 18-85 years old

          -  Patient with symptomatic coronary artery diseases involving two or more vessels
             requiring percutaneous coronary intervention

        Exclusion Criteria:

          -  Patient who is unable to give consent

          -  Patient in acute myocardial infarction or unstable angina

          -  Patient who is hemodynamically unstable

          -  Patient who is allergic to contrast agents

          -  Patient who is allergic to anti-platelet agents

          -  Patient who is allergic to zotarolimus

          -  Patient who is allergic to biolimus

          -  Patient who is pregnant

          -  Patient who has planned surgery in the following 12 months after percutaneous coronary
             intervention

          -  Left main coronary lesion

          -  Bifurcation lesion

          -  Chronic total occlusion lesion

          -  Coronary vessel size smaller than 2.5mm

          -  Coronary lesion longer than 38mm in length
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Wai Luen LEE, MD FRCP FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary Hosptial, The Univeristy of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Cardiology, Department of Medicine, QMH</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <results_reference>
    <citation>Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R; RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002 Jun 6;346(23):1773-80.</citation>
    <PMID>12050336</PMID>
  </results_reference>
  <results_reference>
    <citation>Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003 Oct 2;349(14):1315-23.</citation>
    <PMID>14523139</PMID>
  </results_reference>
  <results_reference>
    <citation>Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004 Jan 15;350(3):221-31.</citation>
    <PMID>14724301</PMID>
  </results_reference>
  <results_reference>
    <citation>Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabaté M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schömig A. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007 Mar 8;356(10):1030-9. Epub 2007 Feb 12.</citation>
    <PMID>17296823</PMID>
  </results_reference>
  <results_reference>
    <citation>Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007 Mar 8;356(10):998-1008. Epub 2007 Feb 12.</citation>
    <PMID>17296824</PMID>
  </results_reference>
  <results_reference>
    <citation>Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006 Dec;119(12):1056-61.</citation>
    <PMID>17145250</PMID>
  </results_reference>
  <results_reference>
    <citation>Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, Sawada T, Paredes OL, Hirata K, Yokoyama M. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography. Eur Heart J. 2007 Apr;28(8):961-7. Epub 2006 Nov 29.</citation>
    <PMID>17135281</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim JS, Fan C, Choi D, Jang IK, Lee JM, Kim TH, Park SM, Paik SI, Ko YG, Hong MK, Jang Y, Chung N. Different patterns of neointimal coverage between acute coronary syndrome and stable angina after various types of drug-eluting stents implantation; 9-month follow-up optical coherence tomography study. Int J Cardiol. 2011 Feb 3;146(3):341-6. doi: 10.1016/j.ijcard.2009.07.012. Epub 2009 Aug 25.</citation>
    <PMID>19709765</PMID>
  </results_reference>
  <results_reference>
    <citation>Barlis P, Regar E, Serruys PW, Dimopoulos K, van der Giessen WJ, van Geuns RJ, Ferrante G, Wandel S, Windecker S, van Es GA, Eerdmans P, Jüni P, di Mario C. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur Heart J. 2010 Jan;31(2):165-76. doi: 10.1093/eurheartj/ehp480. Epub 2009 Nov 4.</citation>
    <PMID>19889649</PMID>
  </results_reference>
  <results_reference>
    <citation>Udipi K, Melder RJ, Chen M, Cheng P, Hezi-Yamit A, Sullivan C, Wong J, Wilcox J. The next generation Endeavor Resolute Stent: role of the BioLinx Polymer System. EuroIntervention. 2007 May;3(1):137-9.</citation>
    <PMID>19737697</PMID>
  </results_reference>
  <results_reference>
    <citation>Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010 Jul 8;363(2):136-46. doi: 10.1056/NEJMoa1004130. Epub 2010 Jun 16.</citation>
    <PMID>20554978</PMID>
  </results_reference>
  <results_reference>
    <citation>Silber S, Windecker S, Vranckx P, Serruys PW; RESOLUTE All Comers investigators. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet. 2011 Apr 9;377(9773):1241-7. doi: 10.1016/S0140-6736(11)60395-4. Epub 2011 Apr 1.</citation>
    <PMID>21459430</PMID>
  </results_reference>
  <results_reference>
    <citation>Grube E, Buellesfeld L. BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease. Expert Rev Med Devices. 2006 Nov;3(6):731-41. Review.</citation>
    <PMID>17280537</PMID>
  </results_reference>
  <results_reference>
    <citation>Grube E, Hauptmann KE, Buellesfeld L, Lim V, Abizaid A. Six-month results of a randomized study to evaluate safety and efficacy of a Biolimus A9 eluting stent with a biodegradable polymer coating. EuroIntervention. 2005 May;1(1):53-7.</citation>
    <PMID>19758877</PMID>
  </results_reference>
  <results_reference>
    <citation>Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Jüni P. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008 Sep 27;372(9644):1163-73. doi: 10.1016/S0140-6736(08)61244-1. Epub 2008 Aug 31.</citation>
    <PMID>18765162</PMID>
  </results_reference>
  <results_reference>
    <citation>Yamaguchi T, Terashima M, Akasaka T, Hayashi T, Mizuno K, Muramatsu T, Nakamura M, Nakamura S, Saito S, Takano M, Takayama T, Yoshikawa J, Suzuki T. Safety and feasibility of an intravascular optical coherence tomography image wire system in the clinical setting. Am J Cardiol. 2008 Mar 1;101(5):562-7. doi: 10.1016/j.amjcard.2007.09.116. Epub 2008 Jan 10.</citation>
    <PMID>18307999</PMID>
  </results_reference>
  <results_reference>
    <citation>Prati F, Cera M, Ramazzotti V, Imola F, Giudice R, Albertucci M. Safety and feasibility of a new non-occlusive technique for facilitated intracoronary optical coherence tomography (OCT) acquisition in various clinical and anatomical scenarios. EuroIntervention. 2007 Nov;3(3):365-70.</citation>
    <PMID>19737719</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2012</study_first_submitted>
  <study_first_submitted_qc>December 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Professor Stephen Lee</investigator_full_name>
    <investigator_title>Professor and Chief of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Stent, OCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

